- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:06 | Cantor Fitzgerald reiterates Overweight rating on CAMP4 Therapeutics stock | 1 | Investing.com | ||
| 14.11. | CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 07.11. | Camp4 Therapeutics reports Q3 results | 1 | Seeking Alpha | ||
| 07.11. | Sana, CAMP4 ditch clinical-stage assets for more promising preclinical candidates | 3 | FierceBiotech | ||
| 02.10. | Cantor Fitzgerald initiates CAMP4 Therapeutics stock with Overweight rating | 1 | Investing.com | ||
| 02.10. | Cantor Fitzgerald startet Coverage für CAMP4 Therapeutics mit "Overweight" | 3 | Investing.com Deutsch | ||
| CAMP4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.10. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10. | CAMP4 Therapeutics begins toxicology studies for SYNGAP1 therapy | 1 | Investing.com | ||
| 01.10. | CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 | 127 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory... ► Artikel lesen | |
| 16.09. | JPMorgan downgrades CAMP4 Therapeutics stock to Neutral on long timeline | 1 | Investing.com | ||
| 15.09. | CAMP4 Therapeutics stock price target lowered to $12 at Piper Sandler | 1 | Investing.com | ||
| 15.09. | Piper Sandler senkt Kursziel für CAMP4 Therapeutics auf 12 US-Dollar | 1 | Investing.com Deutsch | ||
| 10.09. | CAMP4 Therapeutics stock soars after $100 million private placement | 4 | Investing.com | ||
| 10.09. | CAMP4 Therapeutics: CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders | 4 | GlobeNewswire (USA) | ||
| 10.09. | Camp4 Therapeutics Corp - 8-K, Current Report | 3 | SEC Filings | ||
| 15.08. | Camp4 Therapeutics GAAP EPS of -$0.62 beats by $0.06, revenue of $1.5M beats by $1.2M | 1 | Seeking Alpha | ||
| 13.05. | CAMP4 Therapeutics: CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights | 275 | GlobeNewswire (Europe) | Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected... ► Artikel lesen | |
| 02.05. | Pre-market Movers: Classover Holdings, Block, Inc., Advantage Solutions, Ardelyx, CAMP4 Therapeutics | 1.034 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Classover Holdings, Inc. (KIDZ) is up over 65% at... ► Artikel lesen | |
| 27.03. | CAMP4 Therapeutics: CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update | 389 | GlobeNewswire (Europe) | - Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic... ► Artikel lesen | |
| 07.01. | CAMP4 Therapeutics: CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones | 411 | GlobeNewswire (Europe) | Data from Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 for the treatment of urea cycle disorders (UCDs) demonstrates favorable safety resultsCompleted dosing in the first two... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 67,44 | -2,12 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants | SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| ARCELLX | 72,69 | +2,61 % | Stifel upgrades Arcellx stock, cites buying opportunity after share weakness | ||
| AVIDITY BIOSCIENCES | 71,60 | +0,35 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| PRAXIS PRECISION MEDICINES | 267,28 | +2,26 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| IMMUNOVANT | 24,810 | +5,31 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails | ||
| COGENT BIOSCIENCES | 40,040 | +2,17 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| QIAGEN | 38,605 | -1,34 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 81,70 | +0,44 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,070 | -3,60 % | Hagens Berman Sobol Shapiro LLP: MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman | SAN FRANCISCO, Nov. 28, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,420 | -1,32 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p - Functional improvement... ► Artikel lesen | |
| VERA THERAPEUTICS | 46,020 | +3,81 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| MINERALYS THERAPEUTICS | 36,050 | -0,28 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 12,800 | -7,38 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting | ? Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 87,81 | -2,31 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis | Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 31,550 | +2,97 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright |
CAMP4 THERAPEUTICS CORP gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,200 (+3,48 %) liegt der Kurs bei 5,940 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CAMP4 THERAPEUTICS CORP finden Sie auf Wallstreet Online.